Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML) (AML F18-FLT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2012 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Hadassah Medical Organization Identifier:
First received: April 16, 2012
Last updated: May 3, 2012
Last verified: April 2012

PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary.

F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.

Acute Myeloid Leucemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Measure of extent and intensity ( by standardized uptake value - SUV) of disease in bone marrow demonstrated on PET/CT images before and after treatment.

Secondary Outcome Measures:
  • prediction of treatment response by dynamics of FLT uptake(by SUV)in comparison to bone marrow biopsy

Estimated Enrollment: 10
Study Start Date: October 2012
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
patients with AML prior and after treatment


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with new diagnosis of AML

Inclusion Criteria:

  • new diagnosis of AML

Exclusion Criteria:

  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01592266

Contact: Marina Orevi, MD

Hadassah Hebrew University Medical Center Not yet recruiting
Jerusalem, Israel
Principal Investigator: Marina Orevi, MD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Responsible Party: Hadassah Medical Organization Identifier: NCT01592266     History of Changes
Other Study ID Numbers: 0112-12-HMO
Study First Received: April 16, 2012
Last Updated: May 3, 2012

Keywords provided by Hadassah Medical Organization:
bone marrow
AML processed this record on April 28, 2017